Healthcare

Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines

Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with...

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,...

AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis...

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in...

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

Icario Launches Benefits Care Card to Bring New Levels of Flexibility to Medicare Advantage Member Rewards and Incentives

User-friendly Card Gives Members Easy Access to Benefits Including OTC Medication, Nutrition, Hearing, Fitness and VisionMINNEAPOLIS, Sept. 15, 2022 (GLOBE...

EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference

CloudMD’s TAiCBT Results in Significant Improvement for PTSD Across Symptom Severity Levels, Trauma Types and Demographics

Recent research study demonstrates that the majority of clients experience reliable improvement in symptoms after just two months of treatmentVANCOUVER,...

error: Content is protected !!